Literature DB >> 19144758

Xenon preconditioning protects against renal ischemic-reperfusion injury via HIF-1alpha activation.

Daqing Ma1, Ta Lim, Jing Xu, Haidy Tang, Yanjie Wan, Hailin Zhao, Mahmuda Hossain, Patrick H Maxwell, Mervyn Maze.   

Abstract

The mortality rate from acute kidney injury after major cardiovascular operations can be as high as 60%, and no therapies have been proved to prevent acute kidney injury in this setting. Here, we show that preconditioning with the anesthetic gas xenon activates hypoxia-inducible factor 1alpha (HIF-1alpha) and its downstream effectors erythropoietin and vascular endothelial growth factor in a time-dependent manner in the kidneys of adult mice. Xenon increased the efficiency of HIF-1alpha translation via modulation of the mammalian target of rapamycin pathway. In a model of renal ischemia-reperfusion injury, xenon provided morphologic and functional renoprotection; hydrodynamic injection of HIF-1alpha small interfering RNA demonstrated that this protection is HIF-1alpha dependent. These results suggest that xenon preconditioning is a natural inducer of HIF-1alpha and that administration of xenon before renal ischemia can prevent acute renal failure. If these data are confirmed in the clinical setting, then preconditioning with xenon may be beneficial before procedures that temporarily interrupt renal perfusion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19144758      PMCID: PMC2663824          DOI: 10.1681/ASN.2008070712

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  25 in total

Review 1.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

2.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.

Authors:  H Zhong; K Chiles; D Feldser; E Laughner; C Hanrahan; M M Georgescu; J W Simons; G L Semenza
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

3.  Risk factors for delayed graft function in cadaveric kidney transplantation: a prospective study of renal function and graft survival after preservation with University of Wisconsin solution in multi-organ donors. European Multicenter Study Group.

Authors:  O H Koning; R J Ploeg; J H van Bockel; M Groenewegen; F J van der Woude; G G Persijn; J Hermans
Journal:  Transplantation       Date:  1997-06-15       Impact factor: 4.939

4.  Differential expression of heme oxygenase-1 and vascular endothelial growth factor in cadaveric and living donor kidneys after ischemia-reperfusion.

Authors:  Francine B C Lemos; Jan N M Ijzermans; Pieter E Zondervan; Annemiek M A Peeters; Sandra van den Engel; Wendy M Mol; Willem Weimar; Carla C Baan
Journal:  J Am Soc Nephrol       Date:  2003-12       Impact factor: 10.121

Review 5.  Ischemic tolerance and endogenous neuroprotection.

Authors:  Ulrich Dirnagl; Roger P Simon; John M Hallenbeck
Journal:  Trends Neurosci       Date:  2003-05       Impact factor: 13.837

6.  Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury.

Authors:  Péter Hamar; Erwei Song; Gabor Kökény; Allen Chen; Nengtai Ouyang; Judy Lieberman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-04       Impact factor: 11.205

7.  Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats.

Authors:  Makiko Matsumoto; Yuichi Makino; Tetsuhiro Tanaka; Hirotoshi Tanaka; Nobuhiro Ishizaka; Eisei Noiri; Toshiro Fujita; Masaomi Nangaku
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

8.  mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.

Authors:  Pradip K Majumder; Phillip G Febbo; Rachel Bikoff; Raanan Berger; Qi Xue; Louis M McMahon; Judith Manola; James Brugarolas; Timothy J McDonnell; Todd R Golub; Massimo Loda; Heidi A Lane; William R Sellers
Journal:  Nat Med       Date:  2004-05-23       Impact factor: 53.440

9.  Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney.

Authors:  Chul Woo Yang; Can Li; Ju Young Jung; Seok Joon Shin; Bum Soon Choi; Sun Woo Lim; Bo Kyung Sun; Yong Soo Kim; Jin Kim; Yoon Sik Chang; Byung Kee Bang
Journal:  FASEB J       Date:  2003-07-18       Impact factor: 5.191

10.  HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration.

Authors:  Christian Grimm; Andreas Wenzel; Matthias Groszer; Helmut Mayser; Mathias Seeliger; Marijana Samardzija; Christian Bauer; Max Gassmann; Charlotte E Remé
Journal:  Nat Med       Date:  2002-06-17       Impact factor: 53.440

View more
  69 in total

Review 1.  [Current developments in xenon research. Importance for anesthesia and intensive care medicine].

Authors:  A Brücken; M Coburn; S Rex; R Rossaint; M Fries
Journal:  Anaesthesist       Date:  2010-10       Impact factor: 1.041

Review 2.  Molecular mechanisms of ischemic preconditioning in the kidney.

Authors:  Pinelopi P Kapitsinou; Volker H Haase
Journal:  Am J Physiol Renal Physiol       Date:  2015-08-26

Review 3.  Remote ischemic preconditioning for kidney protection: GSK3β-centric insights into the mechanism of action.

Authors:  Zhangsuo Liu; Rujun Gong
Journal:  Am J Kidney Dis       Date:  2015-08-10       Impact factor: 8.860

4.  Impaired wound healing in hypoxic renal tubular cells: roles of hypoxia-inducible factor-1 and glycogen synthase kinase 3β/β-catenin signaling.

Authors:  Jianping Peng; Ganesan Ramesh; Lin Sun; Zheng Dong
Journal:  J Pharmacol Exp Ther       Date:  2011-10-18       Impact factor: 4.030

Review 5.  Non-pharmaceutical therapies for stroke: mechanisms and clinical implications.

Authors:  Fan Chen; Zhifeng Qi; Yuming Luo; Taylor Hinchliffe; Guanghong Ding; Ying Xia; Xunming Ji
Journal:  Prog Neurobiol       Date:  2014-01-07       Impact factor: 11.685

Review 6.  Noble gases as cardioprotectants - translatability and mechanism.

Authors:  Kirsten F Smit; Nina C Weber; Markus W Hollmann; Benedikt Preckel
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

7.  Authors' Reply to Anoop Balachandran et al.: Comment on "Sub-Anesthetic Xenon Increases Erythropoietin Levels in Humans: A Randomized Controlled Trial".

Authors:  Christian Stoppe; Julia Ney; Rolf Rossaint; Mark Coburn; Andreas Goetzenich
Journal:  Sports Med       Date:  2017-02       Impact factor: 11.136

Review 8.  Pharmacologic neuroprotective strategies in neonatal brain injury.

Authors:  Sandra E Juul; Donna M Ferriero
Journal:  Clin Perinatol       Date:  2013-12-12       Impact factor: 3.430

9.  Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in a rat model of thromboembolic stroke.

Authors:  Hélène N David; Benoît Haelewyn; Jean-Jacques Risso; Nathalie Colloc'h; Jacques H Abraini
Journal:  J Cereb Blood Flow Metab       Date:  2010-01-20       Impact factor: 6.200

10.  Xenon anesthesia improves respiratory gas exchanges in morbidly obese patients.

Authors:  Antonio Abramo; Claudio Di Salvo; Francesca Foltran; Francesco Forfori; Marco Anselmino; Francesco Giunta
Journal:  J Obes       Date:  2010-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.